Show simple item record

dc.contributor.authorEnocsson, Helena
dc.contributor.authorWirestam, Lina
dc.contributor.authorDahle, Charlotte
dc.contributor.authorPadyukov, Leonid
dc.contributor.authorJönsen, Andreas
dc.contributor.authorUrowitz, Murray B
dc.contributor.authorGladman, Dafna D
dc.contributor.authorRomero-Diaz, Juanita
dc.contributor.authorBae, Sang-Cheol
dc.contributor.authorFortin, Paul R
dc.contributor.authorSanchez-Guerrero, Jorge
dc.contributor.authorClarke, Ann E
dc.contributor.authorBernatsky, Sasha
dc.contributor.authorGordon, Caroline
dc.contributor.authorHanly, John G
dc.contributor.authorWallace, Daniel J
dc.contributor.authorIsenberg, David A
dc.contributor.authorRahman, Anisur
dc.contributor.authorMerrill, Joan T
dc.contributor.authorGinzler, Ellen
dc.contributor.authorAlarcón, Graciela S
dc.contributor.authorChatham, W Winn
dc.contributor.authorPetri, Michelle
dc.contributor.authorKhamashta, Munther
dc.contributor.authorAranow, Cynthia
dc.contributor.authorMackay, Meggan
dc.contributor.authorDooley, Mary Anne
dc.contributor.authorManzi, Susan
dc.contributor.authorRamsey-Goldman, Rosalind
dc.contributor.authorNived, Ola
dc.contributor.authorSteinsson, Kristjan
dc.contributor.authorZoma, Asad A
dc.contributor.authorRuiz-Irastorza, Guillermo
dc.contributor.authorLim, S Sam
dc.contributor.authorKalunian, Kenneth C
dc.contributor.authorInanc, Murat
dc.contributor.authorvan Vollenhoven, Ronald F
dc.contributor.authorRamos-Casals, Manuel
dc.contributor.authorKamen, Diane L
dc.contributor.authorJacobsen, Søren
dc.contributor.authorPeschken, Christine A
dc.contributor.authorAskanase, Anca
dc.contributor.authorStoll, Thomas
dc.contributor.authorBruce, Ian N
dc.contributor.authorWetterö, Jonas
dc.contributor.authorSjöwall, Christopher
dc.date.accessioned2020-03-12T14:49:26Z
dc.date.available2020-03-12T14:49:26Z
dc.date.issued2019-10-17
dc.date.submitted2020-03
dc.identifier.citationEnocsson H, Wirestam L, Dahle C, et al. Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. J Autoimmun. 2020;106:102340. doi:10.1016/j.jaut.2019.102340en_US
dc.identifier.pmid31629628
dc.identifier.doi10.1016/j.jaut.2019.102340
dc.identifier.urihttp://hdl.handle.net/2336/621320
dc.descriptionTo access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Downloaden_US
dc.description.abstractObjective: The soluble urokinase plasminogen activator receptor (suPAR) has potential as a prognosis and severity biomarker in several inflammatory and infectious diseases. In a previous cross-sectional study, suPAR levels were shown to reflect damage accrual in cases of systemic lupus erythematosus (SLE). Herein, we evaluated suPAR as a predictor of future organ damage in recent-onset SLE. Methods: Included were 344 patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort who met the 1997 American College of Rheumatology classification criteria with 5-years of follow-up data available. Baseline sera from patients and age- and sex-matched controls were assayed for suPAR. Organ damage was assessed annually using the SLICC/ACR damage index (SDI). Results: The levels of suPAR were higher in patients who accrued damage, particularly those with SDI≥2 at 5 years (N = 32, 46.8% increase, p = 0.004), as compared to patients without damage. Logistic regression analysis revealed a significant impact of suPAR on SDI outcome (SDI≥2; OR = 1.14; 95% CI 1.03-1.26), also after adjustment for confounding factors. In an optimized logistic regression to predict damage, suPAR persisted as a predictor, together with baseline disease activity (SLEDAI-2K), age, and non-Caucasian ethnicity (model AUC = 0.77). Dissecting SDI into organ systems revealed higher suPAR levels in patients who developed musculoskeletal damage (SDI≥1; p = 0.007). Conclusion: Prognostic biomarkers identify patients who are at risk of acquiring early damage and therefore need careful observation and targeted treatment strategies. Overall, suPAR constitutes an interesting biomarker for patient stratification and for identifying SLE patients who are at risk of acquiring organ damage during the first 5 years of disease.en_US
dc.description.sponsorshipSwedish Rheumatism Association Region Ostergotland (ALF Grants) King Gustaf V's 80-year Anniversary Foundation King Gustaf V and Queen Victoria's Freemasons Foundation Versus Arthritis National Institute for Health Research (NIHR) NIHR/Welcome Trust Manchester Clinical Research Facility Lupus UK Sandwell and West Birmingham Hospitals NHS Trust National Institute for Health Research (NIHR)/Wellcome Trust Birmingham Clinical Research Facility United States Department of Health & Human Services National Institutes of Health (NIH) - USA National Research Foundation of Koreaen_US
dc.language.isoenen_US
dc.publisherAcademic Pressen_US
dc.relation.urlhttps://www.sciencedirect.com/science/article/pii/S0896841119305554?via%3Dihuben_US
dc.rightsCopyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.
dc.subjectBiomarkeren_US
dc.subjectOrgan damageen_US
dc.subjectOutcomeen_US
dc.subjectPrognosisen_US
dc.subjectSLEen_US
dc.subject.meshBiomarkersen_US
dc.subject.meshLupus Erythematosus, Systemicen_US
dc.titleSoluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus.en_US
dc.typeArticleen_US
dc.identifier.eissn1095-9157
dc.contributor.department1Rheumatology/Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. Electronic address: helena.enocsson@liu.se. 2Rheumatology/Division of Neuro and Inflammation Sciences, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. 3Department of Clinical Immunology and Transfusion Medicine and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. 4Department of Medicine, Division of Rheumatology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden. 5Department of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden. 6Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, Ontario, Canada. 7Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico. 8Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea. 9Division of Rheumatology, CHU de Québec - Université Laval, Quebec City, Canada. 10Division of Rheumatology, Cumming School of Medicine University of Calgary, Calgary, Alberta, Canada. 11Division of Rheumatology, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada. 12Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. 13Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada. 14Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. 15Centre for Rheumatology Research, University College, London, UK. 16Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA. 17Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, USA. 18Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA. 19Department of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 20Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, King's College London School of Medicine, London, UK. 21Feinstein Institute for Medical Research, Manhasset, NY, USA. 22Division of Rheumatology and Immunology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA. 23Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, USA. 24Northwestern University and Feinberg School of Medicine, Chicago, IL, USA. 25Department of Rheumatology, Center for Rheumatology Research Fossvogur, Landspitali University Hospital, Reykjavik, Iceland. 26Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, Scotland, UK. 27Autoimmune Disease Unit, Department of Internal Medicine, Hospital Universitario Cruces, BioCruces Health Research Institute, University of the Basque Country, Barakaldo, Spain. 28Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, USA. 29UCSD School of Medicine, La Jolla, CA, USA. 30Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey. 31Amsterdam University Medical Centres, University of Amsterdam, Amsterdam, Netherlands; Free University (VU) Amsterdam, Amsterdam, Netherlands; Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands. 32Josep Font Autoimmune Diseases Laboratory, IDIBAPS, Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Spain. 33Division of Rheumatology, Medical University of South Carolina, Charleston, SC, USA. 34Copenhagen Lupus and Vasculitis Clinic, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. 35Department of Medicine and Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada. 36Division of Rheumatology, Columbia University Medical Center, New York, USA. 37Department of Rheumatology, Kantousspital, Schaffhausen, Switzerland. 38Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospital NHS Foundation Trust, Manchester Academic Health Science Center, Manchester, UK.en_US
dc.identifier.journalJournal of autoimmunityen_US
dc.rights.accessOpen Access - Opinn aðganguren_US
dc.departmentcodeRHE12
dc.source.journaltitleJournal of autoimmunity
dc.source.volume106
dc.source.beginpage102340
dc.source.endpage
refterms.dateFOA2020-03-12T14:49:27Z
dc.source.countryEngland


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
Soluble ....pdf
Size:
1.291Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record